Nagy JA - Search Results

1

Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.

Sitohy B, Chang S, Sciuto TE, Masse E, Shen M, Kang PM, Jaminet SC, Benjamin LE, Bhatt RS, Dvorak AM, Nagy JA, Dvorak HF. Sitohy B, et al. Among authors: nagy ja. Am J Pathol. 2017 Oct;187(10):2337-2347. doi: 10.1016/j.ajpath.2017.06.010. Epub 2017 Jul 21. Am J Pathol. 2017. PMID: 28736316 Free PMC article.

2

Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.

Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF. Nagy JA, et al. J Exp Med. 2002 Dec 2;196(11):1497-506. doi: 10.1084/jem.20021244. J Exp Med. 2002. PMID: 12461084 Free PMC article.

3

Permeability properties of tumor surrogate blood vessels induced by VEGF-A.

Nagy JA, Feng D, Vasile E, Wong WH, Shih SC, Dvorak AM, Dvorak HF. Nagy JA, et al. Lab Invest. 2006 Aug;86(8):767-80. doi: 10.1038/labinvest.3700436. Epub 2006 May 29. Lab Invest. 2006. PMID: 16732297 Free article.

4

VEGF-A and the induction of pathological angiogenesis.

Nagy JA, Dvorak AM, Dvorak HF. Nagy JA, et al. Annu Rev Pathol. 2007;2:251-75. doi: 10.1146/annurev.pathol.2.010506.134925. Annu Rev Pathol. 2007. PMID: 18039100 Review.

5

Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay.

Nagy JA, Shih SC, Wong WH, Dvorak AM, Dvorak HF. Nagy JA, et al. Methods Enzymol. 2008;444:43-64. doi: 10.1016/S0076-6879(08)02803-6. Methods Enzymol. 2008. PMID: 19007660

6

Vascular permeability and pathological angiogenesis in caveolin-1-null mice.

Chang SH, Feng D, Nagy JA, Sciuto TE, Dvorak AM, Dvorak HF. Chang SH, et al. Among authors: nagy ja. Am J Pathol. 2009 Oct;175(4):1768-76. doi: 10.2353/ajpath.2009.090171. Epub 2009 Sep 3. Am J Pathol. 2009. PMID: 19729487 Free PMC article.

7

Heterogeneity of the tumor vasculature.

Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Nagy JA, et al. Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20. Semin Thromb Hemost. 2010. PMID: 20490982 Free PMC article. Review.

8

Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Sitohy B, Nagy JA, Jaminet SC, Dvorak HF. Sitohy B, et al. Among authors: nagy ja. Cancer Res. 2011 Nov 15;71(22):7021-8. doi: 10.1158/0008-5472.CAN-11-1693. Epub 2011 Sep 21. Cancer Res. 2011. PMID: 21937680 Free PMC article.

9

Anti-VEGF/VEGFR therapy for cancer: reassessing the target.

Sitohy B, Nagy JA, Dvorak HF. Sitohy B, et al. Among authors: nagy ja. Cancer Res. 2012 Apr 15;72(8):1909-14. doi: 10.1158/0008-5472.CAN-11-3406. Cancer Res. 2012. PMID: 22508695 Free PMC article. Review.

10

Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.

Nagy JA, Dvorak HF. Nagy JA, et al. Clin Exp Metastasis. 2012 Oct;29(7):657-62. doi: 10.1007/s10585-012-9500-6. Epub 2012 Jun 13. Clin Exp Metastasis. 2012. PMID: 22692562 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters